Little is known about the prevalence and cumulative burden of coexisting health conditions including chronic joint and muscular pain, urinary incontinence (UI), depression, osteoporosis risk, moderate/severe vasomotor symptoms, and vulvar/vaginal atrophy (VVA). We surveyed a nationally representative U.S. sample of midlife (age 40–64 years) women to ascertain the prevalence, general health-related quality of life (HRQoL), and health-seeking behaviors associated with these six conditions.
Methods:
This cross-sectional, telephone survey collected data from a sample of English- and Spanish-speaking U.S. women. The survey contained demographic and menopausal status questions, and also five condition-specific symptom/disease risk-screening instruments. The EuroQol 5 dimensions (EQ-5D) questionnaire was used to measure HRQoL. Health-seeking behavior was measured based on clinician discussion of and recent treatment for each condition.
Results:
Three thousand fifty eight women (mean age 53.4 years) completed the survey. The majority were white (75.6%), married (60.5%), employed full- or part-time (59.0%), and postmenopausal (69.8%; based on self-report). The prevalence [95% confidence interval] of 0, 1, 2, and ≥3 conditions was 35.2% [33.5–36.9], 34.2% [32.5–35.9], 17.9% [16.6–19.3], and 12.7% [11.5–13.9], respectively. Osteoporosis risk (30.6%) was most prevalent, followed by VVA (27.8%) and UI (26.6%). UI and VVA coexisted most frequently (11.3%), followed by osteoporosis risk and VVA (9.8%). EQ-5D scores decreased with increasing number of illnesses (0, 1, 2, and ≥3 conditions, means: 0.92, 0.87, 0.77, 0.61, respectively; p<0.01). Health-seeking behavior varied by condition.
Conclusion:
Over 25% of women surveyed had multiple coexisting conditions. Lower HRQoL was associated with multiple conditions and with each added condition.
Get full access to this article
View all access options for this article.
References
1.
NygaardI, BarberMD, BurgioKL, et al.Prevalence of symptomatic pelvic floor disorders in US women. JAMA, 2008; 300:1311–1316.
2.
KesslerRC. National Comorbidity Survey 2005. Appendix table 1: Lifetime prevalence of DSM-IV/WMH-CIDI disorders by sex and cohort. Cambridge, MA: Harvard Medical School, 2005;Available at www.hcp.med.harvard.edu/ncs/ftpdir/table_ncsr_by_gender_and_age.pdf Accessed May10, 2012.
3.
LookerAC, MeltonLJIII, HarrisTB, BorrudLG, ShepherdJA. Prevalence and trends in low femur bone density among older US adults: NHANES 2005–2006 compared with NHANES III. J Bone Miner Res, 2010; 25:64–71.
4.
WolfeF, RossK, AndersonJ, RussellIJ, HebertL. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum, 1995; 38:19–28.
5.
GoldEB, ColvinA, AvisNet al.Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of women's health across the nation. Am J Public Health, 2006; 96:1226–1235.
6.
NappiRE, Kokot-KierepaM. Women's voices in the menopause: Results from an international survey on vaginal atrophy. Maturitas, 2010; 67:233–238.
7.
SranMM. Prevalence of urinary incontinence in women with osteoporosis. J Obstet Gynaecol Can, 2009; 31:434–439.
8.
RitenbaughC, PattersonRE, ChlebowskiRTet al.The Women's Health Initiative Dietary Modification trial: Overview and baseline characteristics of participants. Ann Epidemiol, 2003; 13:S87–S97.
9.
StefanickML, CochraneBB, HsiaJ, BaradDH, LiuJH, JohnsonSR. The Women's Health Initiative postmenopausal hormone trials: Overview and baseline characteristics of participants. Ann Epidemiol, 2003; 13:S78–S86.
10.
LangerRD, WhiteE, LewisCE, KotchenJM, HendrixSL, TrevisanM. The Women's Health Initiative Observational Study: Baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol, 2003; 13:S107–S121.
11.
ColditzGA, MansonJE, HankinsonSE. The Nurses' Health Study: 20-year contribution to the understanding of health among women. J Womens Health, 1997; 6:49–62.
12.
TownsendMK, CurhanGC, ResnickNM, GrodsteinF. The incidence of urinary incontinence across Asian, black, and white women in the United States. Am J Obstet Gynecol, 2010; 202:378–7.
BrombergerJT, SchottLL, KravitzHM, et al.Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: Results from the Study of Women's Health Across the Nation (SWAN). Arch Gen Psychiatry, 2010; 67:598–607.
15.
FinkelsteinJS, BrockwellSE, MehtaV, et al.Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab, 2008; 93:861–868.
16.
WaetjenLE, LiaoS, JohnsonWO, et al.Factors associated with prevalent and incident urinary incontinence in a cohort of midlife women: A longitudinal analysis of data: Study of women's health across the nation. Am J Epidemiol, 2007; 165:309–318.
17.
FortinM, BravoG, HudonC, et al.Relationship between multimorbidity and health-related quality of life of patients in primary care. Qual Life Res, 2006; 15:83–91.
18.
AgborsangayaCB, LauD, LahtinenM, CookeT, JohnsonJA. Health-related quality of life and healthcare utilization in multimorbidity: Results of a cross-sectional survey. Qual Life Res, 2013; 22:791–799.
19.
FortinM, LapointeL, HudonC, VanasseA, NtetuAL, MaltaisD. Multimorbidity and quality of life in primary care: A systematic review. Health Qual Life Outcomes, 2004; 2:51.
20.
SullivanPW, GhushchyanVH, BaylissEA. The impact of co-morbidity burden on preference-based health-related quality of life in the United States. Pharmacoeconomics, 2012; 30:431–442.
21.
de Souza SMV, ValadaresAL, da Costa-PaivaLS, MoraesSS, Pinto-NetoAM. Multimorbidity and associated factors in Brazilian women aged 40 to 65 years: A population-based study. Menopause, 2012; 19:569–575.
22.
HowdenL, MeyerJ. 2010. Census briefs: Age and sex composition. Washington, DC: U.S. Department of Commerce, Economics and Statistics Administration, U.S. Census Bureau, 2011. Available at: URL: www.census.gov/prod/cen2010/briefs/c2010br-03.pdf Accessed May14, 2012.
23.
DennyDL, GuidoGW. Undertreatment of pain in older adults: An application of beneficence. Nurs Ethics, 2012; 19:800–809.
24.
LewisV. Undertreatment of menopausal symptoms and novel options for comprehensive management. Curr Med Res Opin, 2009; 25:2689–2698.
25.
KrothPJ, MurrayMD, McDonaldCJ. Undertreatment of osteoporosis in women, based on detection of vertebral compression fractures on chest radiography. Am J Geriatr Pharmacother, 2004; 2:112–118.
26.
Women's Health Initiative (WHI). Concept review document on the clinical trial and the observational studies. Bethesda, MD: National Instituttes of Health, WHI, March 9, 1992.
27.
Women's Health Initiative. Manual of operations and procedures, vol. 2. Bethesda, MD: National Instituttes of Health, WHI, May, 1993.
28.
CadaretteSM, JaglalSB, KreigerN, et al. Development and validation of the Osteoporosis Risk Assessment Instrument to facilitate selection of women for bone densitometry. CMAJ, 2000; 162:1289–1294.
29.
WhiteKP, HarthM, SpeechleyM, OstbyeT. Testing an instrument to screen for fibromyalgia syndrome in general population studies: The London Fibromyalgia Epidemiology Study screening questionnaire. J Rheumatol, 1999; 26:880–884.
30.
BrownJS, BradleyCS, SubakLLet al.The sensitivity and specificity of a simple test to distinguish between urge and stress urinary incontinence. Ann Intern Med, 2006; 144:715–723.
31.
KroenkeK, SpitzerRL, WilliamsJB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med, 2001; 16:606–613.
32.
U.S. Food and Drug Administration. Guidance for industry: Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms Recommendations for clinical evaluation. Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2003.
33.
EuroQol—A new facility for the measurement of health-related quality of life. Health Policy, 1990; 16:199–208.
34.
Calculating the U.S. population-based EQ-5D™ Index Score: Research Initiative in clinical economics. Rockville, MD: Agency for Healthcare Research and Quality, 2005August Available at: www.ahrq.gov/rice/EQ5Dscore.htm Accessed May10, 2012.
35.
ShawJW, JohnsonJA, CoonsSJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care, 2005; 43:203–220.
36.
EuroQol Group. EQ-5D: A standardized instrument for use as a measure of health outcome. Rotterdam: EuroQol Group, 2013
37.
McDowellI, NewellC. Measuring health: a guide to rating scales and questionnaires. 2nd rev. ed ed. New York: Oxford University Press; 1996.
38.
WaltersSJ, BrazierJE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res, 2005; 14:1523–1532.
39.
FriedLP, Bandeen-RocheK, KasperJD, GuralnikJM. Association of comorbidity with disability in older women: The Women's Health and Aging Study. J Clin Epidemiol, 1999; 52:27–37.
40.
Medical Expenditure Panel Survey (MEPS). Rockville, MD: Agency for Healthcare Research and Quality (AHRQ), 2003.
41.
SullivanPW, GhushchyanV. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making, 2006; 26:410–420.
42.
JonesJ, MosherW, DanielsK. Current contraceptive use in the United States, 2006–2010, and changes in patterns of use since 1995. Hyattsville, MD: National Center for Health Statistics, 2012.
43.
SpragueBL, Trentham-DietzA, CroninKA. A sustained decline in postmenopausal hormone use: Results from the National Health and Nutrition Examination Survey, 1999–2010. Obstet Gynecol, 2012; 120:595–603.
44.
JohannesCB, LeTK, ZhouX, JohnstonJA, DworkinRH. The prevalence of chronic pain in United States adults: Results of an Internet-based survey. J Pain, 2010; 11:1230–1239.
45.
LookerAC, BorrudLG, Dawson-HughesB, ShepherdJA, WrightNC. Osteoporosis or low bone mass at the femur neck or lumbar spine in older adults: United States, 2005–2008. Hyattsville, MD: National Center for Health Statistics, 2012.
46.
WilliamsRE, KalilaniL, DiBenedettiDBet al.Frequency and severity of vasomotor symptoms among peri- and postmenopausal women in the United States. Climacteric, 2008; 11:32–43.
47.
Mac BrideMB, RhodesDJ, ShusterLT. Vulvovaginal atrophy. Mayo Clin Proc, 2010; 85, 87–94.
48.
WhiteleyJ, DibonaventuraMD, WagnerJS, AlvirJ, ShahS. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J Womens Health (Larchmt), 2013; 22:983–990.
